Kadcyla

Chemical Nameado-trastuzumab emtansine
Dosage FormInjection (intravenous; 100 mg, 160 mg)
Drug ClassInhibitors
SystemFemale reproductive
CompanyGenentech
Approval Year2013

Indication

  • For the treatment of patients who received prior therapy for metastatic disease with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.
  • For the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
Last updated on 6/23/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Kadcyla (ado-trastuzumab emtansine) Prescribing Information.2022Genentech, Inc., South San Francisco, CA